BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32650834)

  • 21. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.
    Brayer KJ; Frerich CA; Kang H; Ness SA
    Cancer Discov; 2016 Feb; 6(2):176-87. PubMed ID: 26631070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of CTNNB1 gene mutations and β-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas.
    Cavalcante RB; Nonaka CFW; Santos HBP; Rabenhorst SHB; Pereira Pinto L; de Souza LB
    Virchows Arch; 2018 Jun; 472(6):999-1005. PubMed ID: 29577164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta-analysis.
    Liu X; Chen D; Lao X; Liang Y
    Head Neck; 2019 May; 41(5):1517-1524. PubMed ID: 30759319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
    Mitani Y; Li J; Rao PH; Zhao YJ; Bell D; Lippman SM; Weber RS; Caulin C; El-Naggar AK
    Clin Cancer Res; 2010 Oct; 16(19):4722-31. PubMed ID: 20702610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma.
    Wang R; Geng N; Zhou Y; Zhang D; Li L; Li J; Ji N; Zhou M; Chen Y; Chen Q
    Biomed Mater Eng; 2015; 26 Suppl 1():S2145-53. PubMed ID: 26405993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.
    Ferrazzo KL; Neto MM; dos Santos E; dos Santos Pinto D; de Sousa SO
    J Oral Pathol Med; 2009 Oct; 38(9):701-7. PubMed ID: 19659475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Submaxillary Gland Androgen-regulated Protein 3A (SMR3A) in Adenoid Cystic Carcinoma of the Head and Neck.
    Thierauf J; Veit JA; Grünow J; Döscher J; Weißinger S; Whiteside T; Beutner D; Quaas A; Plinkert P; Hoffmann TK; Hess J
    Anticancer Res; 2016 Feb; 36(2):611-5. PubMed ID: 26851015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
    Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
    Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
    Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival.
    Schneider S; Thurnher D; Seemann R; Brunner M; Kadletz L; Ghanim B; Aumayr K; Heiduschka G; Lill C
    Eur Arch Otorhinolaryngol; 2016 May; 273(5):1283-92. PubMed ID: 25801951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Claudin-7 Inhibits Proliferation and Metastasis in Salivary Adenoid Cystic Carcinoma Through Wnt/β-Catenin Signaling.
    Ji H; Ding X; Zhang W; Zheng Y; Du H; Zheng Y; Song H; Li M; Jiang Y; Xie J; Wu M; Jiao P; Wang Z; Wu H; Zhong Y
    Cell Transplant; 2020; 29():963689720943583. PubMed ID: 32749148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
    Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of xenograft model systems for adenoid cystic carcinoma.
    Moskaluk CA; Baras AS; Mancuso SA; Fan H; Davidson RJ; Dirks DC; Golden WL; Frierson HF
    Lab Invest; 2011 Oct; 91(10):1480-90. PubMed ID: 21709671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYB Translocations in Both Myoepithelial and Ductoglandular Epithelial Cells in Adenoid Cystic Carcinoma: A Histopathologic and Genetic Reappraisal in Six Primary Cutaneous Cases.
    Goto K; Kajimoto K; Sugino T; Nakatsuka SI; Yoshida M; Noto M; Kono M; Takai T
    Am J Dermatopathol; 2021 Apr; 43(4):278-283. PubMed ID: 32732690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis.
    Li Q; Huang P; Zheng C; Wang J; Ge M
    Oncotarget; 2017 Apr; 8(17):29458-29473. PubMed ID: 28206977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma.
    Bell D; Bell A; Roberts D; Weber RS; El-Naggar AK
    Cancer; 2012 Mar; 118(5):1288-92. PubMed ID: 21800291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics.
    von Holstein SL; Fehr A; Persson M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
    Ophthalmology; 2013 Oct; 120(10):2130-8. PubMed ID: 23725736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance.
    Sun J; Luo Y; Tian Z; Gu L; Xia SC; Yu Y
    BMC Cancer; 2012 Oct; 12():499. PubMed ID: 23110497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients.
    Friedrich RE; Bleckmann V
    Anticancer Res; 2003; 23(2A):931-40. PubMed ID: 12820326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
    Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.